Idiopathic Pulmonary Fibrosis in Type 2 Diabetes Mellitus
- 1 March 2025
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Respiratory Medicine Reviews
- Vol. 21 (2) , 118-124
Abstract
Type 2 Diabetes Mellitus (T2DM) is a chronic condition that afflicts millions of people worldwide. T2DM correlates with increased levels of pro-inflammatory and pro-fibrotic molecules and respiratory cell injury leading to Idiopathic Pulmonary Fibrosis (IPF) development. Idiopathic pulmonary fibrosis patients with T2DM have a higher rate of progression and worse prognosis, including higher hospital stay length and mortality rate. On High-resolution Computed Tomography (HRCT), IPF patients with T2DM are more likely to exhibit the Usual Interstitial Pneumonia (UIP) pattern (reticular and honeycomb patterns) than those without T2DM. Interventions for IPF include non-pharmacological interventions, i.e., oxygen supplementation and pulmonary rehabilitation, and pharmacological interventions, including nintedanib and pirfenidone. Antidiabetic agents, such as metformin, thiazolidinediones, and glucagon-like peptide 1, have shown anti-pulmonary fibrotic effects and to be associated with better clinical outcomes.Keywords
This publication has 45 references indexed in Scilit:
- Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in miceThe Clinical Respiratory Journal, 2024
- Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical StudiesAdvances in Therapy, 2023
- Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health recordsNature Medicine, 2022
- Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPDChest, 2021
- Gut-Lung Dysbiosis Accompanied by Diabetes Mellitus Leads to Pulmonary Fibrotic Change through the NF-κB Signaling PathwayThe American Journal of Pathology, 2021
- Diabetic lung disease: fact or fiction?Reviews in Endocrine and Metabolic Disorders, 2019
- Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisChest, 2019
- Diabetes induces fibrotic changes in the lung through the activation of TGF-β signaling pathwaysScientific Reports, 2018
- A prospective study of the impact of diabetes mellitus on restrictive and obstructive lung function impairment: The Saku studyMetabolism, 2018
- How does comorbidity influence survival in idiopathic pulmonary fibrosis?Respiratory Medicine, 2014